



Letairis[®] (ambrisentan) – First-time generic

- On April 11, 2019, Sun launched an [AB-rated](#) generic version of Gilead Sciences' [Letairis \(ambrisentan\)](#) tablets.
 - [Mylan](#), [Teva](#), [Zydus](#), [Par](#), and [Sigmapharm](#) received FDA approval of AB-rated generic versions of Letairis. Launch plans are pending for these generics.
- Letairis is approved for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability and delay clinical worsening; and in combination with [tadalafil](#) to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability.
- Letairis carries a boxed warning for embryo-fetal toxicity.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.